Annexon, Inc..
ANNX.US | Manufacture of pharmaceuticals, medicinal chemical and botanical products
Annexon, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapies for classical complement-mediated autoimmune, neurodegenerative, and ophthalmic diseases. The company's lead product candidate, ANX005, is a monoclonal antibody designed to block C1q, the initiating mol...Show More
Better Health for All
0
Annexon's entire business is devoted to developing novel therapies for severe autoimmune, neurodegenerative, and ophthalmic diseases, demonstrating a fundamental commitment to health improvement.
1
Its ANX005 product showed a 2.4-fold improvement on the GBS-DS in a Phase 3 trial, along with a median of 28 fewer days on artificial ventilation and a 31-day reduction in time to walk independently.
2
The company is clinical-stage and currently generates no revenue from products, thus having no harmful revenue share.
3
It maintains high ethical standards in clinical trials, complying with global good clinical practices, obtaining Independent Review Committee approval, and ensuring informed consent.
4
All Phase II-IV clinical trials are accurately and timely submitted to clinicaltrials.gov.
5
The company also applies appropriate confidentiality rules and stores data in compliance with data protection laws, including HIPAA.
6
However, Annexon acknowledges its investigational therapies are not approved as safe and effective and does not offer access outside of clinical trials.
7
One article questioned the transparency of ANX007 trial results, suggesting potential cherry-picking of data after the primary outcome was negative.
8
The company's health equity efforts are primarily internal, focusing on workforce diversity, with no evidence of external programs addressing health disparities.
9
There is no specific data on the affordability of its products or the extent to which vulnerable populations obtain equitable access to its therapies, beyond conducting GBS trials in regions where IVIg treatment is not readily available to ethically provide a placebo-controlled dataset.
10
Fair Money & Economic Opportunity
0
Annexon, Inc. is a biopharmaceutical company focused on developing therapies, not a financial institution.
1
The company does not offer lending, deposit, or other financial services to consumers.
2
Therefore, all KPIs related to financial products, services, and customer financial outcomes are not applicable. Evidence regarding patient financial assistance, internal diversity initiatives, investor information access, or R&D investment does not fall under the scope of 'Fair Money & Economic Opportunity' as defined for financial services.
Fair Pay & Worker Respect
0
No specific, concrete data points were found across the provided articles for any of the KPIs under the 'Fair Pay & Worker Respect' value. While some articles mention policies related to equal opportunity, non-retaliation, and compliance with health and safety laws, these are not quantitative metrics or substantiated incidents required by the rubric.
1
Information on CEO pay was provided, but median employee pay was not, preventing the calculation of the CEO-to-median pay ratio.
2
Employee reviews offered subjective opinions but no formal engagement scores or turnover rates.
3
Therefore, all KPIs are omitted due to lack of evidence.
Fair Trade & Ethical Sourcing
0
No specific, quantitative data regarding Annexon, Inc.'s fair trade and ethical sourcing practices, such as fair-trade certification share, audit frequency, forced or child labor incidents, supply chain traceability, remediation speed, ethical clause coverage in contracts, materials risk index, or supplier diversity spend, was provided in the available article.
1
Honest & Fair Business
-20
The company has a comprehensive Code of Business Conduct and Ethics applicable to all directors, officers, and employees, which includes an ethics helpline available 24/7 for anonymous reporting.
1
The policy prohibits retaliation against whistle-blowers, and reports are reviewed by a Compliance Officer and reported to the Audit Committee.
2
The company has not had any financial restatements recently.
3
The board has determined that all directors, except one, qualify as independent, indicating 6 out of 7 directors are independent.
4
The company has an anti-corruption policy that includes training for all employees on anti-bribery and anti-corruption policies and explicitly prohibits giving anything of value to foreign officials under the U.S. Foreign Corrupt Practices Act.
5
The Compensation Committee retains an independent executive compensation consulting firm to assess executive and director compensation programs.
6
Kind to Animals
-40
Annexon, Inc. conducts animal testing for pre-clinical studies and drug development, using animal models to assess product safety and efficacy, such as ANX007 reducing retinal damage.
1
These animal studies are conducted in compliance with regulations including the Animal Welfare Act and Public Health Service Policy.
2
While in vitro binding studies are performed using human and cynomolgus monkey C1q, indicating some use of non-animal methods, the company still relies on animal testing for complex endpoints.
3
Specific studies mentioned involved a total of 34 cynomolgus monkeys across single and repeat dose trials.
4
The company's policy permits animal testing for pre-clinical studies and drug development, aligning with legal mandates in the biopharmaceutical sector.
5
No War, No Weapons
0
No information was found in the provided articles regarding Annexon, Inc.'s involvement in arms manufacturing, military contracts, dual-use technology, sales to embargoed regimes, peacebuilding investments, or any other activities related to the 'No War, No Weapons' ethical value.
1
Therefore, no KPIs could be scored.
Planet-Friendly Business
0
No specific, concrete data points or facts regarding Annexon, Inc.'s performance on any of the Planet-Friendly Business KPIs were found in the provided articles. While Article 5 mentions a USGBC project page for ANNX.US, it explicitly states that no article content or data is available from that source.
1
Therefore, no assessment can be made against these metrics.
Respect for Cultures & Communities
0
The provided articles do not contain specific quantitative data or concrete actions relevant to any of the 'Respect for Cultures & Communities' KPIs. Information available pertains to general ESG risk ratings
1
and internal diversity, equity, and inclusion initiatives
2
, which do not map to the specified external community and cultural respect metrics such as formal partnerships, community reinvestment, cultural appropriation incidents, impact assessments, local employment, grievance mechanisms, or cultural preservation.
Safe & Smart Tech
0
The company states it aims to prevent unauthorized data use by detecting and preventing illegal activities.
1
Users can request access to, amendment, or deletion of their personal information by contacting the company via email.
2
The company states it is subject to and aims for consistency with various laws, rules, and regulations, including information privacy laws and HIPAA.
3
It also files all required reports with the SEC, including quarterly reports on Form 10-Q, and has submitted all required Interactive Data Files.
4
Zero Waste & Sustainable Products
0
No specific, concrete data points were found in the provided articles regarding Annexon, Inc.'s performance on any of the KPIs related to Zero Waste & Sustainable Products.
1
The articles did not contain information on waste diversion, product recyclability, packaging sustainability, recycled content, single-use plastic reduction, take-back programs, circular design, waste reduction initiatives, hazardous waste management, product durability, repairability, waste audit frequency, zero waste certification, waste disposal violations, material efficiency, packaging-to-product ratio, waste reduction targets, supplier waste requirements, or customer waste education.
2